As of 2025-07-09, the Intrinsic Value of Clinigen Group PLC (CLIN.L) is 559.41 GBP. This CLIN.L valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 925.00 GBP, the upside of Clinigen Group PLC is -39.50%.
The range of the Intrinsic Value is 387.36 - 888.89 GBP
Based on its market price of 925.00 GBP and our intrinsic valuation, Clinigen Group PLC (CLIN.L) is overvalued by 39.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 387.36 - 888.89 | 559.41 | -39.5% |
| DCF (Growth 10y) | 684.33 - 1,380.87 | 924.84 | -0.0% |
| DCF (EBITDA 5y) | 653.11 - 1,675.67 | 1,037.53 | 12.2% |
| DCF (EBITDA 10y) | 873.32 - 2,056.14 | 1,311.04 | 41.7% |
| Fair Value | 464.51 - 464.51 | 464.51 | -49.78% |
| P/E | 1,011.69 - 2,112.12 | 1,496.25 | 61.8% |
| EV/EBITDA | 584.06 - 5,351.72 | 2,082.83 | 125.2% |
| EPV | 477.67 - 654.92 | 566.29 | -38.8% |
| DDM - Stable | 412.18 - 953.67 | 682.93 | -26.2% |
| DDM - Multi | 412.66 - 739.18 | 529.40 | -42.8% |
| Market Cap (mil) | 1,231.64 |
| Beta | 1.66 |
| Outstanding shares (mil) | 1.33 |
| Enterprise Value (mil) | 1,527.24 |
| Market risk premium | 5.34% |
| Cost of Equity | 9.92% |
| Cost of Debt | 4.26% |
| WACC | 8.05% |